1142 results about "Lung cancer cell" patented technology

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

A high-accuracy lung cancer cell image recognizing method with low false negative rate includes taking the photo of pathological cell section by digital camera on optical microscope, picking up the video image by image pick-up device, sending it to computer, pre-processing, and recognizing by lung cancer cell image recognizing unit consisting of two-stage neural network.

The invention discloses polypeptide for specifically targeting a lung cancer cell and an application thereof. The polypeptide for specifically targeting the lung cancer cell has an amino acid sequence shown as SEQ ID NO.1, and is prepared by screening on the surface of the human lung cancer cell by an ex-vivo bacterial random polypeptide library exhibiting method and a flow cell sorting method. The polypeptide for specifically targeting the lung cancer cell can be applied to preparation of lung cancer diagnosing tracer, lung cancer cell detecting reagent and the like. The polypeptide for specifically targeting the lung cancer cell can be combined with a lung cancer A549 cell specifically, is not combined with a normal lung cell and other tumor cells; and the preparation method is simple, feasible and applicable to large-scale industrial production. The polypeptide for specifically targeting the lung cancer cell provides important theoretical and practical basis for early diagnosis, targeting therapy of the lung cancer and the like, and has a wide application prospect.

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with lung cancer. The biological compositions can be used to retard the growth of lung cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

The invention relates to a traditional Chinese medicine composition for curing lung cancer and belongs to the field of the traditional Chinese medicine. The composition comprises 16 kinds of Chinese herbal medicines including astragalus, bittersweet herb, akebia stem, tendril-leaved fritillary bulb, barbed skullcap herb, poria cocos, lily, platycodon grandiflorum, cordate houttuynia, house lizard, cordyceps sinensis, leech, radix stemonae, bungarus parvus, radix glehniae and subprostrate sophora. The composition has effects of invigorating qi for consolidating superficies, moistening lung for arresting cough, resolving sputum and reliving asthma, activating blood and removing stasis, diminishing inflammation and relieving pain; and has obvious inhibition effect on growth and spread of lung cancer cells, can relieve lung cancer symptoms remarkably, and is exact in curative effect, high in effective rate and particularly suitable for curing non-small cell lung cancer in advanced stage.